A significant number of patients demonstrated a favorable response to the drug DS-8201a (ORR 37–79.9%) in the analyzed research, demonstrating the treatment’s effectiveness for patients with HER2-positive breast and gastric cancer. The gene discussed is ERBB2; the disease is gastric cancer.